Neurogene Inc. (NGNE)

Neurogene's stock was impacted by several events in the past six months. The stock soared after NGN-401 received FDA Breakthrough Therapy designation. The company reported its full-year 2025 financial results and provided updates on its clinical programs, including the progress of NGN-401, and announced that the Embolden™ registrational trial for NGN-401 was fully enrolled. Fintel increased Neurogene's price target. Neurogene announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. Neurogene announced upcoming presentations on the therapeutic rationale for ICV delivery in CNS-targeted gene therapy.

There is no indication of significant demand seasonality for Neurogene, Inc.'s products and services. Demand is driven by the prevalence and progression of rare neurological diseases, as well as the success of its clinical trials and regulatory approvals.

Neurogene, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases, operating within the Healthcare sector and Biotechnology industry. The company's strategy includes its EXACT™ transgene regulation platform, which aims to deliver therapeutic levels of gene expression while mitigating transgene toxicity. Neurogene's lead clinical program is NGN-401, an investigational AAV9 gene therapy for Rett syndrome, which has received multiple regulatory designations. Another product candidate is NGN-101, a conventional gene therapy designed to treat CLN5 Batten disease.

Neurogene, Inc. is headquartered in New York, New York, and has a gene therapy manufacturing facility in Houston, Texas. The company plans to expand its clinical footprint into Europe, pending regulatory clearances, and has expanded its U.S. clinical footprint to 13 sites.

Neurogene's brand reputation is largely positive due to clinical advancements and scientific approach. The FDA Breakthrough Therapy Designation for NGN-401, positive interim clinical data, expansion of clinical footprint, and strategic appointments have positively impacted its reputation. However, a stock drop in November 2024, following interim clinical data for NGN-401, had a temporary negative impact.

Neurogene Inc. has a mixed ownership structure, including institutional, retail, and individual investors. Major institutional owners include Samsara BioCapital, LLC, Redmile Group, LLC, and RTW Investments, LP. Individual insiders own approximately 8.26% of the company's shares, with recent selling activity by Julie Jordan, Rachel McMinn, and Christine Cvijic. Rachel McMinn is also listed as a top shareholder.